drugset / Trial / NCT05604885
A Dose-range Study of the Safety and Efficacy of Treatment in Adult Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate
RandomizedParallel-groupTriple-blindTreatment
Summary
The RESOLVE study is a two-part, randomized, double-blind, multi-center, placebo-controlled study of the safety, dose-range finding confirmation, and efficacy of 4 (Part A) and 12 weeks (Part B) of treatment with AP1189 in adult RA patients with an inadequate response to MTX alone.
Timeline
- Start
- 2022-11-30
- Primary completion
- 2023-08-28
- Completion
- 2023-08-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Resomelagon | Small molecule | 60 mg | Oral |
| Subject | Resomelagon | Small molecule | 80 mg | Oral |
| Subject | Resomelagon | Small molecule | 100 mg | Oral |